EGO-COMBO Clinical End-point Extension Study Beyond 36 Months
Launched by THE UNIVERSITY OF HONG KONG · Oct 7, 2014
Trial Information
Current as of July 24, 2025
Completed
Keywords
ClinConnect Summary
The Genous Stent (the EPC Capture R-stent, OrbusNeich Medical Inc., Fort Lauderdale, FL) is commercially available and has been used extensively in standard coronary intervention in the treatment of more than 200 patients with critical coronary stenoses at Queen Mary Hospital. The COMBO Stent (OrbusNeich Medical Inc., Fort Lauderdale, FL) is an improved version of the Genous Stent and is now widely available for clinical use in all Hong Kong hospitals. To date, more than 300 patients in Queen Mary Hospital have received the COMBO stent as treatment for their coronary artery disease, and all...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient previously participated in EGO-COMBO Pilot Study (UW 10-342)
- Exclusion Criteria:
- • Patient not previously participated in EGO-COMBO Pilot Study (UW 10-342)
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, Hong Kong, China
Patients applied
Trial Officials
Wai Luen Stephen LEE, MD
Principal Investigator
The Univeristy of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials